FDA Agreement on Mesoblast’s Use of Singapore Manufacturing Facility for MPCs Clinical Trial Production

News   May 21, 2013

 
FDA Agreement on Mesoblast’s Use of Singapore Manufacturing Facility for MPCs Clinical Trial Production
 
 
 

RELATED ARTICLES

Uptake of Controlled Release Drug Delivery Technology Set to Increase?

News

The increasing access to healthcare facilities and the bolstering need for drugs to be used orally has been driving the consumption of generic drugs among people across the world, which, in turn, is fueling the need for controlled release technology for drug delivery to suffice the availability of drugs in small dosages.

READ MORE

Immune Response Restored in Patients with Melanoma Thanks to New Compound

News

A novel compound may restore immune response in patients with melanoma, according to a study presented at the ESMO Immuno Oncology Congress 2017.

READ MORE

Zika Vaccine Trials Provide Promising Results

News

Researchers report that an investigational Zika vaccine was well-tolerated and stimulated potentially protective immune responses in three Phase 1 clinical trials,

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Cell Science

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE